U.S. FDA Rejects Eisai’s Aquavan Injection
This article was originally published in PharmAsia News
Executive Summary
Despite a recent advisory panel vote recommending clearance, albeit with strings attached, U.S. FDA has deemed Eisai's Aquavan, a mild-to-moderate sedative for colonoscopies and other procedures, "not approvable.
You may also be interested in...
Eisai Wins Approval Of Sedative Lusedra, But Without Main Marketing Advantage
U.S. FDA approved Eisai's intravenous sedative-hypnotic agent Lusedra (fospropofol), but without the marketing advantage the company was hoping it would used to help differentiate the anesthetic from its competitors
Eisai Wins Approval Of Sedative Lusedra, But Without Main Marketing Advantage
U.S. FDA approved Eisai's intravenous sedative-hypnotic agent Lusedra (fospropofol), but without the marketing advantage the company was hoping it would used to help differentiate the anesthetic from its competitors
Shionogi Gains U.S. Sales Force With $1.4 Billion Sciele Acquisition
TOKYO - Shionogi moved Sept. 1 to establish a sales presence in the U.S. through the acquisition of Atlanta-based Sciele Pharma. Boards of both firms approved the $1.42 billion purchase, for $31 per share, prior to the announcement